首頁(yè) > 產(chǎn)品中心 > 科研抗體 > 標(biāo)記一抗
產(chǎn)品中心
相關(guān)產(chǎn)品
標(biāo)記一抗
英文名稱Anti-AADAC/FITC
中文名稱:FITC標(biāo)記的芳香乙酰胺脫乙酰基酶抗體
別 名AAAD_HUMAN; Aada; Aadac; Arylacetamide deacetylase (esterase); Arylacetamide deacetylase; CES5A1; DAC.
規(guī)格:100ul
說(shuō) 明 書100ul
研究領(lǐng)域腫瘤 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo)
抗體來(lái)源Rabbit
克隆類型Polyclonal
交叉反應(yīng) Human, Mouse, Rat, Pig, Cow, Horse, Rabbit, Sheep,
產(chǎn)品應(yīng)用ICC=1:50-200 IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量46kDa
細(xì)胞定位細(xì)胞膜
性 狀Lyophilized or Liquid
濃 度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human AADAC (228-273aa)
亞 型IgG
純化方法affinity purified by Protein A
儲(chǔ) 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹background:
The assembly of very-low-density lipoproteins (VLDLs) in the secretory apparatus of the hepatocyte relies on the mobilization of triacylglycerol (TAG) from the cytosolic pool by lipolysis and re-esterification. However, some of the re-esterified TAG products are returned to the cytosolic pool in the liver, which protects vulnerable body tissues from excess lipotoxic non-esterified fatty acids in the plasma. Some of the lipases involved in this process include arylacetamide deacetylase (AADAC) and its related proteins AADACL1 and AADACL2. AADAC, a single pass type II membrane protein of the endoplasmic reticulum, is expressed in hepatocytes, intestinal mucosal cells, pancreas and adrenal gland. It plays an important role in the metabolic activation of arylamine substrates to ultimate carcinogens. AADACL1 hydrolyzes the metabolic intermediate 2-acetyl monoalkylglycerol, and its inactivation results in disruption of ether lipid metabolism in cancer cells and impaired cell migration and tumor growth
Function:
Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionaly causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.
Subcellular Location:
Endoplasmic reticulum membrane. Microsome membrane.
Tissue Specificity:
Mainly expressed in liver, small intestine, colon and adrenal gland.
Similarity:
Belongs to the 'GDXG' lipolytic enzyme family.
Database links:
UniProtKB/Swiss-Prot: P22760.5
中文名稱:FITC標(biāo)記的芳香乙酰胺脫乙酰基酶抗體
別 名AAAD_HUMAN; Aada; Aadac; Arylacetamide deacetylase (esterase); Arylacetamide deacetylase; CES5A1; DAC.
詳細(xì)介紹：
規(guī)格:100ul
說(shuō) 明 書100ul
研究領(lǐng)域腫瘤 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo)
抗體來(lái)源Rabbit
克隆類型Polyclonal
交叉反應(yīng) Human, Mouse, Rat, Pig, Cow, Horse, Rabbit, Sheep,
產(chǎn)品應(yīng)用ICC=1:50-200 IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量46kDa
細(xì)胞定位細(xì)胞膜
性 狀Lyophilized or Liquid
濃 度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human AADAC (228-273aa)
亞 型IgG
純化方法affinity purified by Protein A
儲(chǔ) 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
相關(guān)資料：
產(chǎn)品介紹background:
The assembly of very-low-density lipoproteins (VLDLs) in the secretory apparatus of the hepatocyte relies on the mobilization of triacylglycerol (TAG) from the cytosolic pool by lipolysis and re-esterification. However, some of the re-esterified TAG products are returned to the cytosolic pool in the liver, which protects vulnerable body tissues from excess lipotoxic non-esterified fatty acids in the plasma. Some of the lipases involved in this process include arylacetamide deacetylase (AADAC) and its related proteins AADACL1 and AADACL2. AADAC, a single pass type II membrane protein of the endoplasmic reticulum, is expressed in hepatocytes, intestinal mucosal cells, pancreas and adrenal gland. It plays an important role in the metabolic activation of arylamine substrates to ultimate carcinogens. AADACL1 hydrolyzes the metabolic intermediate 2-acetyl monoalkylglycerol, and its inactivation results in disruption of ether lipid metabolism in cancer cells and impaired cell migration and tumor growth
Function:
Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionaly causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.
Subcellular Location:
Endoplasmic reticulum membrane. Microsome membrane.
Tissue Specificity:
Mainly expressed in liver, small intestine, colon and adrenal gland.
Similarity:
Belongs to the 'GDXG' lipolytic enzyme family.
Database links:
UniProtKB/Swiss-Prot: P22760.5
